（論文：原著） - u-toyama.ac.jp articles since...1 （論文：原著） year 1979...

1

（論文：原著）

Year 1979

１．折笠秀樹、籏野修一、開原成允（1979）

脳卒中の予後規定因子の解析．

日本医事新報. No.2896: 23-29.

２．折笠秀樹（1979）

病院におけるコンピュータ利用対象業務の傾向分析：統計学的手法の応用．

病院学. 3: 19-29.

３．日本病院会コンピュータ委員会（1979）-統計解析担当者として関与-

病院におけるコンピュータ利用の実態．

日本病院会雑誌. 26(5): 1-26.

４．折笠秀樹、三宅浩之（1979）

病院経営分析指標の評価．

社会保険旬報. No. 1304: 1-5.

Year 1980

５．折笠秀樹、三宅浩之（1980）

日本におけるコンピュータ利用に関する意識構造分析．

日本病院会雑誌. 27(10): 18-28.

Year 1981

None

Year 1982

６．折笠秀樹（1982）

Ｃｏｘの回帰モデルを用いた丸山ワクチンの評価について．

逓信医学. 34(10): 657-659.

７．折笠秀樹、三宅浩之（1982）

臨床薬物速度論へのコンピュータ応用．

医療情報学. 4(4): 317-328.

８．折笠秀樹、三宅浩之（1982）

多変量解析の病院経営分析への応用．

日本病院会雑誌. 28(7): 13-28.

Year 1983

2

9．折笠秀樹、三宅浩之（1983）

チャーノフ顔グラフを用いた病院経営状態の分析．

日本病院会雑誌. 29(6); 17-25.

10．Origasa H, Miyake H, Sawasaki H.（1983）

Administration of medical records in Japanese hospitals: a status report.

Med Inform. 8(2): 109-125.

11. Origasa H, Watanabe Y, Miyake H, Sawasaki H.（1983）

Statistical association between the medical record management and the level of performing

information processing.

Med Inform. 8(4): 265-278.

Year 1984

None

Year 1985

12．Origasa H.（1985）

Statistical models for plasma concentrations of a drug following Michaelis-Menten equation.

Master of Science Thesis, Dept. of Biostatistics, Univ. of North Carolina.

Year 1986

None

Year 1987

None

Year 1988

13．Origasa H（1988）

Statistical Methods for the Analysis of Longitudinal Data with Binary Responses.

Ph.D. Dissertation, Dept. of Biostatistics, Univ.of North Carolina.

Year 1989

None

Year 1990

14．Origasa H, Knoke JD.（1990）

A comparative study of two statistical models for the analysis of binary data from longitudinal

3

studies.

Environmental Health Perspectives. 87: 143-147．

Year 1991

15．Peoples-Sheps MD, Siegel E, Suchindran CM, Origasa H, Ware A, Barakat A.（1991）

Characteristics of maternal employment during pregnancy: Effects on low

birthweight.

Am J Public Health. 81: 1007-1012．

Year 1992

Year 1993

None

Year 1994

16. 山本和利、坂口明、折笠秀樹、柳沼淑夫、金澤康徳（1994）

インスリン抵抗性と血圧値の関係．

日本公衆衛生雑誌. 41: 230-236.

17. 日本泌尿器科学会共同研究検討小委員会（1994） -メンバーとして参画-

泌尿器科癌臨床試験ガイドライン．

日本泌尿器科学会雑誌. 85: 1143-1153.

18. 飯沼宏之、春見健一、杉本恒明、松尾博司、宮原英夫、笠貫宏、大江透、小川聡、田辺晃久、加藤貴雄、井

上博、魚井徹、折笠秀樹、前田博（1994）

日本における不整脈薬物療法の現状 -JALT調査報告・その１-

日本医事新報. No.3654: 47-52.

19. 飯沼宏之、春見健一、杉本恒明、松尾博司、宮原英夫、笠貫宏、大江透、小川聡、田辺晃久、加藤貴雄、井

上博、魚井徹、折笠秀樹、前田博（1994）

日本における不整脈薬物療法の現状 -JALT調査報告・その２-

日本医事新報. No.3687: 25-27.

Year 1995

20. 折笠秀樹（1995）

日本の臨床試験への疑問点．

医学のあゆみ. 174: 865-869.

Year 1996

4

21. 酒井弘憲、林邦彦、折笠秀樹、陣内紀恵、楠正(1996)

高血圧薬剤治療における有害事象評価へのメタアナリシスの応用.

薬剤疫学 . 1(1): 39-40.

22. 山田和生、細田瑳一、岸田浩、谷口興一、中島光好、折笠秀樹、飯村攻、栗田明、横山光宏（1996）

狭心症患者の運動耐容能を指標とした塩酸エホニジピン（ＮＺ‐１０５）の薬効評価 -ニフェジピン

持効錠を対照薬とした多施設二重盲検比較試験-

基礎と臨床. 30: 3433-3464.

23. 山田和生、谷口興一、岸田浩、中島光好、折笠秀樹、飯村攻、稲垣義明、楠川礼造、篠山重威（1996）

塩酸 efonidipine（NZ‐105５）の狭心症に対する臨床評価 -Nifedipine持効錠を対照薬とした多施設

二重盲検比較試験-

基礎と臨床. 30: 3403-3432.）

24. 児玉和久、河合忠一、細田瑳一、青木延雄、高野照夫、上松瀬勝男、本宮武司、由井芳樹、折笠秀樹（1996）

急性心筋梗塞に対する YM866（改変型 t‐PA）の単回静脈内投与における至適投与量検討のための多施

設二重盲検群間比較試験 -後期第 II相試験-

新薬と臨床. 45: 2031-2063.

25. 由井芳樹、河合忠一、細田瑳一、青木延雄、高野照夫、上松瀬勝男、本宮武司、住吉徹哉、南野隆三、児玉

和久、土師一夫、佐藤光、延吉正清、折笠秀樹（1996）

急性心筋梗塞に対する YM866（改変型 t-PA）の単回静脈内投与における有用性に関する検討

新薬と臨床. 45: 2175-2210.

Year 1997

26. 三輪剛、三好秋馬、竹本忠良、松尾裕、浅木茂、中村孝司、森治樹、岩崎有良、原澤茂、中澤三郎、小林旬

三、勝健一、早川晃、佐藤慎吉、折笠秀樹、中島光好（1997）

Z-103の胃炎に対する臨床評価-スクラルファートを対照薬とした二重盲検比較試験-

薬理と治療. 25: 1195-1236.

27. 太田和夫、佐中孜、平沢由平、中川雅夫、中川成之輔、秋澤忠男、折笠秀樹（1997）

血液透析時対外循環における低分子ヘパリン KM-311 （一般名：レベパリンナトリウム）の抗凝血薬と

しての臨床的検討-多施設共同第 II相臨床試験-

臨床医薬. 13: 1941-1959.

28. 太田和夫、佐中孜、平沢由平、中川雅夫、中川成之輔、秋澤忠男、折笠秀樹（1997）

出血性病変ないし出血傾向を有する患者の血液透析時対外循環における低分子ヘパリン KM-311 （一般

名：レベパリンナトリウム）の抗凝血薬としての臨床的検討-多施設共同第 II相臨床試験-

臨床医薬. 13: 1961-1976.

29. 太田和夫、佐中孜、平沢由平、中川雅夫、秋澤忠男、折笠秀樹(1997)

慢性腎不全患者の血液透析時対外循環における抗凝血薬 KM-311 （一般名：レベパリンナトリウム）の

臨床評価-未分画ヘパリンを対照薬とした二重盲検交差比較試験-

5

臨床医薬. 13: 2589-2618.

30. 太田和夫、佐中孜、平沢由平、中川雅夫、秋澤忠男、折笠秀樹(1997)

出血性病変を有する透析患者の血液透析時対外循環における低分子ヘパリン KM-311 （一般名：レベパ

リンナトリウム）の臨床評価ーダルテパリンナトリウムを対照薬とした二重盲検並行群間比較試験ー

臨床医薬. 13: 2619-2645.

31. Owa M, Origasa H, Saito M. (1997)

Predictive validity of the Braunwald classification of unstable angina for

angiographic findings, short-term prognoses, and treatment selection.

Angiology. 48: 663-671.

32. 山本祐香理、折笠秀樹、佐藤均、井上博、林隆一(1997)

降圧薬の処方パターンと合併疾患の関係-院内データを用いた薬剤使用調査-

薬剤疫学. 2(2): 83-89.

33. 水口弘司、藤本征一郎、佐藤和雄、武谷雄二、麻生武志、岡田弘二、本庄英雄、大濱紘三、青野敏博、永田

行博、折笠秀樹(1997)

RG93933 (E2パッチ）第 III相臨床試験.

臨床医薬. 13: 4513-4528.

34. Origasa H. (1997)

Cumulating the scientific evidences in cardiology with a special reference to Japanese

contribution.

Heart and Vessels. 41 (suppl.12): 142-147.

35. 篠原幸人、折笠秀樹(1997)

メタアナリシスを用いた脳循環代謝改善薬臨床効果の再検討．

脳卒中. 19(4): 308-317.

Year 1998

36. 太田和夫、佐中孜、平沢由平、中川雅夫、中川成之輔、秋澤忠男、折笠秀樹(1998)

KM-311（一般名：レビパリンナトリウム）の安定期血液透析患者に対する長期臨床試験．

臨床医薬. 14(3): 533-566.

Year 1999

37. 内潟安子、折笠秀樹、坂巻弘之、岩本安彦(1999)

糖尿病の医療経済学的分析 -合併症医療費の検討-

糖尿病 42(9)： 743-750.

38. Tagaki S, Tanaka O, Origasa H, Miura Y.(1999)

The prognostic significance of femoral marrow magnetic resonance imaging in patients with

myelodysplastic syndromes.

6

J Clin Oncol. 17(1): 277-283.

39. Sakai H, Hayashi K, Origasa H, Kusunoki T.(1999)

An application of meta-analysis techniques in the evaluation of adverse experiences with

anti-hypertensive agents.

Pharmacoepidemiology and Drug Safety. 8: 169-177.

Year 2000

40. 折笠秀樹、久野貞子、長谷川一子、水野美邦(2000)

パーキンソン病の重症度を測る日本語版 UPDRS 尺度の信頼性評価．

神経治療学 17(6): 577-591.

41. Kazumi T, Kikkawa R, Yoshino G, Nakashima M, Origasa H, Baba S(2000)

Long-term effect of nifedipine retard versus enalapril therapy on the incidence of cardiovascular

events in hypertensive type 2 diabetic patients.

Eur Heart J Suppl. 2(D): 33-34.

Year 2001

42. Hirashima Y, Takashima S, Matsumura N, Kurimoto M, Origasa H, Endo S(2001)

Right sylvian fissure subarachnoid hemorrhage has electrocardiographic consequences.

Stroke 32: 2278-2281.

43. Baba S and The J-MIND Study Group (2001), participated as a statistician

Nifedipine retard or enalapril for nephropathy in hypertensive type 2 diabetics.

Diabetes Research and Clinical Practice 54: 191-201.

Year 2002

44. Antithrombotic Trialists’ (ATT) Collaboration(2002), 折笠秀樹は Collaborator として参画

Prevention of death, myocardial infarction and stroke by antiplatelet therapy: collaborative

meta-analysis of 266 trials involving 200,000 patients at high risk of occlusive vascular events.

Br Med J, 324: 71-86.

45. Ogawara M, Kawahara M, Hosoe S, Atagi S, Kawaguchi T, Okishio K, Naka N, Sunami T, Mitsuoka S, Inoue

K, Haryu H, Yoneda T, Origasa H(2002)

A feasibility study of paclitaxel 225mg/m2 and carboplatin AUC=6 in untreated advanced non-small

cell lung cancer patients in Japan.

Jap J Clin Oncol. 32(2): 48-53.

46. Hamamichi Y, Ichida F, Tsubata S, Hirono K, Watanabe S, Rui C, Yu X, Uese K, Hashimoto I, Simizu

M, Seto H, Origasa H, Miyawaki T(2002)

Dobutamine stress radionuclide ventriculography reveals silent myocardial dysfunction in

7

Kawasaki disease

Circulation Journal. 66(1):63-69.

47. Kawaguchi A, Mitsudo K, Nobuyoshi M, Minamino R, Hayasaki K, Nakashima M, Yamamoto A, for the ATHEROMA

Study Group(2002), 折笠秀樹は Statisticianとして参画

Angiographic intervention trial using HMG CoA reductase inhibitor to evaluate retardation of

obstructive multiple atheroma in West-Japan (ATHEROMA Study): Rationale, design, and baseline.

J Cardiovasc Risk. 9: 7-16.

48. Atarashi H, Inoue H, Fukunami M, Sugi K, Hamada C, Origasa H, for the Sinum Rhythm maintenance in

Atrial Fibrillation Randomized Trial (SMART) Investigators(2002)

Double-blind placebo-controlled trial of aprindine and digoxin for the prevention of symptomatic

atrial fibrillation.

Circulation J. 66: 553-556.

49. Hirashima Y, Kuwayama N, Kubo M, Origasa H, Endo S(2002)

Chlamydia pneumoniae infection is not involved in carotid artery stenosis.

Atherosclerosis. 163: 165-168.

50. Kakumu S, Matsushima T, Sato S, Kobayashi K, Kiyosawa K, Hayashi N, Tsuji T, Sata M, Origasa H, Iino

S, and the RAM Study Group (2002)

Serum HCV RNA levels during early phase recombinant interferon alfa-2a (Roferon A) therapy for

chronic hepatitis C and efficacy of short-term therapy with earlier loss of viremia.

Hepatol Res. 22: 152-160.

51. Koizumi J, Shimizu M, Miyamoto S, Origasa H, Mabuchi H, for the Hokuriku Lipid CHD Study Group(2002)

Effect of pravastatin-induced LDL-cholesterol reduction on coronary heart disease and

cerebrovascular disease in Japanese: Hokuriku Lipid Coronary Heart Disease Study –Pravastatin

Atherosclerosis Trial (Holicos-PAT).

Journal of Atherosclerosis and Thrombosis. 9(5): 251-259.

52. 朱燕波、折笠秀樹、王琦(2002)

鍼治療の腰痛への臨床効果 -VAS 値を評価指標としたメタアナリシス-

薬理と治療. 30: 997-1002.

53. 佐野靖之、宮本康文、荒井康男、田中康子、秋山法久、折笠秀樹(2002)

Salmeterol xinafoate (SN408)吸入用散剤の臨床的検討（第 3報）

臨床医薬. 18: 705-717.

54. 佐野靖之、宮本康文、荒井康男、田中康子、秋山法久、折笠秀樹(2002)

Salmeterol xinafoate (SN408)吸入用散剤の臨床的検討（第 4報）

臨床医薬 2002; 18: 719-731.

55. Hosoe S, Komuta K, Shibata K, Harada H, Iwamoto Y, Osaki Y, Morioka T, Origasa H, Fukushima M, Furuse

K, Kawahara M(2003)

8

Gemcitabine and vinorelbine followed by docetaxel in patients with advanced non-small cell lung

cancer: a multi-institutional phase II trial of nonplatinum sequential triplet combination

chemotherapy(JMTO LC00-02).

Br J Cancer. 88; 342-347.

Year 2003

56. Hirashima Y, Hamada H, Hayashi N, Kuwayama N, Origasa H, Endo S(2003)

Independent predictors of late hydrocephalus in patients with aneurismal subarachnoid hemorrhage

-Analysis by multivariate logistic regression model.

Cerebrovascular Diseases. 16: 205-210.

57. Yamamoto H, Hirashima Y, Hamada H, Hayashi N, Origasa H, Endo S(2003)

Independent predictors of the recurrence of chronic subdural hematoma – Multivariate analysis

using a logistic regression model.

J Neurosurg. 98: 1217-1221.

58. Hirayama A, Kodama K, Yui Y, Nonogi H, Sumiyoshi T, Origasa H, Hosoda S, Kawai C, for the JMIC(M)

Investigators(2003)

Effect of trapidil on cardiovascular events in patients with coronary artery disease (results

from the Japan Multicenter Investigation for Cardiovascular Diseases – Mochida [JMIC-M]).

Am J Cardiol. 92: 789-793.

59. Yokoyama A, Origasa H, for the JELIS Investigators(2003)

Effects of eicosapentanenoic acid on cardiovascular events in Japanese patients with

hypercholesterolemia: Rational, design, and baseline characteristics of the Japan EPA Lipid

Intervention Study (JELIS).

Am Heart J. 146: 613-620.

60. Araie M, Kitazawa Y, Azuma I, Shirato S, Hamanaka T, Tomita G, Origasa H(2003)

The efficacy and safety of dose escalation of dorzolamide used in combination with other topical

antiglaucoma agents.

J Ocular Pharmacol Ther. 19(6): 517-525.

61. Mizuno Y, Yanagisawa N, Kuno S, Yamamoto M, Hasegawa K, Origasa H, Kowa H, for the Japanese Pramipexole

Study Group(2003)

Randomized, double-blind study of pramipexole with placebo and bromocriptine in advanced

Parkinson's disease.

Movement Disorders. 18(10):1149-56.

62. 横山奈緒美、折笠秀樹(2003)

日本語版 WHO-QOL-26 の妥当性.

薬理と治療. 31(9): 737-43, 2003.

9

63. 栗原怜、鈴木正司、二瓶宏、秋沢忠男、衣笠えり子、折笠秀樹､越川昭三(2003)

血液透析患者の高リン血症に対するリン結合剤 PB-94(Sevelamer Hydrochloride)の効果―第 II 相用量

設定試験.

腎と透析. 55(1): 221-238.

64. 鈴木正司、栗原怜、大園英一、北岡建樹、千田佳子、衣笠えり子、中山文義、笹岡拓雄、山崎親雄、辻本吉

広、小野利彦、打田和宏、大森浩之、川西秀樹、折笠秀樹、越川昭三(2003)

血液透析患者の高リン血症に対すリン結合剤 PB-94(Sevelamer Hydrochloride)の効果―沈降炭酸カルシ

ウム製剤（カルタン錠 500）を対照とした比較臨床試験―

腎と透析. 55(2): 383-400.

65. 大森浩之、鈴木正司、栗原怜、大園英一、北岡建樹、千田佳子、衣笠えり子、小岩文彦、中山文義、笹岡拓

雄、山崎親雄、辻本吉広、小野利彦、打田和宏、川西秀樹、折笠秀樹、越川昭三(2003)

血液透析患者の高リン血症に対するリン結合剤 PB-94(Sevelamer Hydrochloride)の効果―長期投与試験

―

腎と透析. 55(3): 513-531.

66. 平松信、東海林隆男、新倉一彦、森田有津子、折笠秀樹、越川昭三(2003)

腹膜透析患者の高リン血症に対するリン結合剤 PB-94(Sevelamer Hydrochloride)の効果―第 III相一般

臨床試験―

腎と透析. 55(4): 653-663.

67. 高井許子、水道裕久、田中敏郎、小谷麻由美、藤田晃人、竹内明、牧野武利、澄川一英、折笠秀樹、辻啓介、

中島光好(2003)

ブロッコリー・キャベツを配合した野菜・果物混合飲料による高コレステロール血症者の血清 LDL-コレ

ステロール低下作用.

臨床病理. 51(11): 1073-1083.

Year 2004

68. Yui Y, Sumiyoshi T, Kodama K, Hirayama A, Nonogi H, Kanmatsuse K, Iimura O, Ishii M, Saruta T, Arakawa

K, Nakashima M, Origasa H, Hosoda S, Kawai C (2004)

Comparison of Nifedipine Retard with Angiotensin Converting Enzyme Inhibitors in Japanese

Hypertensive Patients with Coronary Artery Disease: The Japan Multicenter Investigation for

Cardiovascular Diseases-B (JMIC-B) Randomized Trial.

Hypertens Researcn. 27: 181-191.

69. Yui Y, Sumiyoshi T, Kodama K, Hirayama A, Nonogi H, Kanmatsuse K, Origasa H, Iimura O, Ishii M, Saruta

T, Arakawa K, Hosoda S, Kawai C(2004)

Nifedipine retard was as effective as angiotensin converting enzyme inhibitors in preventing

cardiac events in high-risk hypertensive patients with diabetes and coronary artery disease:

the Japan Multicenter Investigation for Cardiovascular Diseases-B (JMIC-B) subgroup analysis.

10

Hypertension Research. 27(7):449-56.

70. Hori M, Sasayama S, Kitabatake A, Toyo-oka T, Handa S, Yokoyama M, Matsuzaki M, Takeshita A, Origasa

H, Matsui K, Hosoda S, on behalf of the MUCHA investigators(2004)

Low-dose carvedilol improves left ventricular function and reduces cardiovascular

hospitalization in Japanese patients with chronic heart failure: The Multicenter Carvedilol Heart

Failure Dose Assessment (MUCHA) Trial.

Am Heart J. 147(2): 324-330.

71. Yamamoto K, Izumi R, Hasegawa K, Nakajima H, Ohashi K, Kudo R, Okuda H, Takahashi T, Origasa H, Sugimori

H (2004)

Adjuvant oral 5-fluorouracil for cervical cancer: Japanese Gynecologic Oncology Group report.

Int J Oncol. 24(5): 1175-1179.

72. Nagahori T, Hirashima Y, Umemura K, Nakagawa H, Kamisaki Y, Origasa H, Endo S(2004)

Association of pontine small infarction (lacnuna) with disturbance of postural stability.

Eur Neurol. 51(3): 138-143.

73. Mizuno K, Nakamura H, Ohashi Y, Kaburagi T, Kitabatake A, Tochihara T, Hosoda S, and the JUST Study

Investigators(2004), 折笠秀樹は Statisticianとして参画

A randomized, open-label, comparative study of simvastatin plus diet versus diet alone on

angiographic retardation of coronary atherosclerosis in adult Japanese patients: Japanese

utilization of simvastatin therapy (JUST) study.

Clinical Therapeutics. 26(6): 878-888.

74. Kogure T, Sato N, Tahara E, Sakai S, Shimada Y, Ochiai H, Origasa H, Terasawa K(2004)

Assessment of effects of traditional herbal medicines on elderly patients with weakness using

a self-controlled trial.

Geriatrics and Gerontology International. 4: 169-174.

75. 朱燕波、折笠秀樹、鄭潔、杜金行(2004)

慢性心功能不全患者的生活質量.

中国臨床康復（Chinese Journal of Clinical Rehabilitation）. 8(15): 2928-2929.

76. Origasa H, Ikeda Y, Shimada K, Shigematsu H (2004)

Oral beraprost sodium as a prostaglandin I2 analogue for vascular events in patients with

peripheral arterial disease: meta-analysis of two placebo-controlled randomized trials.

Jap J Pharmacoepidemiol. 9(2): 45-51.

Year 2005

77. Sasayama S, Kunieda T, Tomoike H, Matsuzaki M, Shirato K, Kuriyama T, Izumi T, Origasa H, van

Giersvergen PLM, Dingemanse J, Tanaka S(2005)

Effects of the endothelin receptor antanogist bosentan on hemodynamics, symptoms and functional

11

capacity in Japanese patients with severe pulmonary hypertension.

Circulation Journal. 69: 131-137.

78. Shimada S, Yokoyama N, Origasa H, Tsuneki H, Kimura I(2005)

Progressive bone loss due to androgen deprivation therapy for prostate cancer: a meta-analysis.

Jpn J Pharm Health Care Sci. 31(3): 203-210.

79. Shimizu M, Koizumi J, Miyamoto S, Origasa H, Mabuchi H, for the HOLICOS-PAT Study Group(2005)

Electrocardiographic events and cholesterol reduction with pravastatin in patients with

hypercholesterolemia: The Hokuriku Lipid Coronary Heart Disease Study – Pravastatin

Atherosclerosis Trial.

Int J Cardiol. 99: 395-401.

80. Koizumi J, Shimizu M, Miyamoto S, Takeda R, Ohka T, Kanaya H, Uno Y, Ueda K, Taketoshi T, Wakasugi

T, Ohta M, Sumitani T, Kametani T, Watanabe A, Fujita H, Hifumi S, Origasa H, Mabuchi H, and the

Hokuriku Lipid CHD Study Group(2005)

Risk evaluation of coronary heart disease and cerebrovascular disease by the Japanese

Atherosclerosis Society Guidelines 2002 using the cohort of the Holicos-PAT study.

Journal of Atherosclerosis and Thrombosis. 12(1): 48-52.

81. Hirashima Y, Hamada H, Kurimoto M, Origasa H, Endo S(2005)

Decrease in platelet count is an independent risk factor for symptomatic vasospasm following

aneurismal subarachnoid hemorrhage.

J Neurosurg. 102: 882-887.

82. Hirashima Y, Kurimoto M, Hayashi N, Umemura K, Hori E, Origasa H, Endo S(2005)

Duration of cerebrospinal fluid drainage in patients with aneurismal subarachnoid hemorrhage

for prevention of symptomatic vasospasm and late hydrocephalus.

Neurologia Medico-Chirurgica. 45(4): 177-82.

83. Gotoh M, Kamihira O, Kinukawa T, Ono Y, Ohshima S, Origasa H, on behalf of the Tokai Urological Clinical

Trial Group(2005)

Comparison of α1a-selective adrenoceptor antagonist, tamsulosin, and α1d-selective adrenoceptor

antagnonist, naftopidil, for efficacy and safety in the treatment of benign prostatic

hyperplasia; a randomized controlled trial

Br J Urol Int. 96: 581-586.

84. Yamamoto H, Ohsawa K, Walz SE, Mitchen JL, Watanabe Y, Eberle R, Origasa H, Sato H(2005)

Validation of an enzyme-linked immunosorbent assay kit of Herpesvirus papio 2 (HVP2) antigen

for detection of Herpesvirus simiae (B virus) infection in rhesus monkeys.

Comparative Medicine. 55: 244-248.

85. Satoh N, Sakai S, Kogure T, Tahara E, Origasa H, Shimada K, Kohoda K, Okubo T, Terasawa K(2005)

A randomized double blind placebo-controlled clinical trial of Hochuekkito, a traditional herbal

12

medicine, in the treatment of elderly patients with weakness N of one and responder restricted

design.

Phytomedicine. 12: 549-554.

86. The J-DHF Program Committee(2005), Origasa H, to be charged for statistical analysis

Rationale and design of a randomized trial to assess the effects of ACE inhibitor and beta-blocker

in diastolic heart failure: Japanese Diastolic Heart Failure Study (J-DHF).

J Cardiac Failure. 11(7): 542-547.

87. Hirashima Y, Kurimoto M, Hori E, Origasa H, Endo S(2005)

Lower incidence of symptomatic vasospasm after subarachnoid hemorrhage owing to ruptured

vertebrobasilar aneurysms.

Neurosurgery. 57: 1110-1116.

88. 田崎美弥子, 石井八重子, 海老原良典, 折笠秀樹, 高山美智代, 広瀬信義, 角間辰之, 加藤芳朗, 国吉緑,

LeeJung Won, 鈴木千智, 長谷川恵美子, 藤井美和, 畑田けい子, 松田正巳, WHOQOL-OLD調査票日本語版開

発グループ(2005)

高齢者の Quality of Life(QOL)調査票開発プロジェクトにおける予備調査結果.

老年精神医学雑誌. 16(2): 221-227.

Year 2006

89. Sakamaki H, Ikeda S, Ikegami N, Uchigata Y, Iwamoto Y, Origasa H, Otani T, Otani Y(2006)

Measurement of HRQL using EQ-5D in patients with type 2 diabetes mellitus in Japan.

Value in Health. 9(1): 47-53.

90. Sato H, Ishikawa K, Kitabatake A, Ogawa S, Maruyama Y, Yokota Y, Fukuyama N, Doi Y, Mochizuki S,

Izumi T, Takegoshi N, Yoshida K, Hiramori K, Origasa H, Uchiyama S, Matsumoto M, Yamaguchi T, Hori

M, on behalf of the Japan Atrial Fibrillation and Stroke Trial (JAST) Group (2006)

Low dose aspirin for prevention of stroke in patients with atrial fibrillation: Japan Atrial

Fibrillation Stroke Trial.

Stroke. 37: 447-451.

Year 2007

91. Mizokami A, Ueno S, Fukagai T, Ito K, Ehara H, Kinbara H, Origasa H, Usami M, Namiki M, Akaza H(2007)

Global update on defining and treating high-risk localized prostate cancer with leuprorelin:

an Asian perspective.

BJU International. 99 (Suppl 1): 6-9.

92. Yokoyama M, Origasa H, Matsuzaki M, Matsuzawa Y, Saito Y, Ishikawa Y, Oikawa S, Sasaki J, Hishida

H, Itakura H, Kita T, Kitabatake A, Nakaya N, Sakata T, Shimada K, Shirato K, for the Japan EPA

Lipid Intervention Study (JELIS) Investigators (2007)

13

Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients

(JELIS): a randomised open-label, blinded endpoint analysis.

Lancet. 369: 1090-1098.

93. The J-MELODIC Program Committee (2007) (Origasa H to be a trial statistician)

Rationale and design of a randomized trial to assess the effects of diuretics in heart failure

– Japanese Multicenter Evaluation of LOng- vs short-acting Diuretics in Congestive heart failure

(J-MELODIC)


94. Yamazaki T, Goto S, Shigematsu H, Shimada K, Uchiyama S, Nagai R, Yamada N, Matsumoto M, Origasa

H, Ikeda Y, for the REACH Registry Investigators (2007)

Prevalence, awareness and treatment of cardiovascular risk factors in patients at high risk of

atherothrombosis in Japan.

Circulation Journal. 71 : 995-1003.

95. 田中俊一、折笠秀樹、赤沼安夫、菊池方利 (2007)

２型糖尿病患者に対する食後高血糖改善薬ミチグリニドの血糖降下作用の検討―プラセボを対照とし

た並行群間比較用量反応試験―.

薬理と治療. 35(suppl): S5-21.

96. 田中俊一、折笠秀樹、赤沼安夫、菊池方利 (2007)

２型糖尿病患者に対する速効性・短時間作用型インスリン分泌促進剤ミチグリニドの長期投与試験.


97. 陶易王、折笠秀樹、赤沼安夫 (2007)

ボグリボース投与中の２型糖尿病患者におけるミチグリニド単回投与による臨床薬理試験.


98. 加来浩平、田中俊一、折笠秀樹、赤沼安夫、菊池方利 (2007)

α―グルコシダーゼ阻害薬ボグリボース治療で血糖コントロール不十分な２型糖尿病患者に対する速

効性・短時間作用型インスリン分泌促進剤ミチグリニドの併用効果―第 II/III相二重盲検比較試験.


99. 遅野井健、荷見澄子、徳島眞彦、新島和、小笠原忠彦、北澤要、星賢二、山口徹、折笠秀樹、赤沼安夫、菊

池方利 (2007)

α―グルコシダーゼ阻害薬ボグリボース治療で血糖コントロール不十分な２型糖尿病患者に対する速

効性・短時間作用型インスリン分泌促進剤ミチグリニドの併用効果―第 III相併用投与試験.


100. 長谷川恵美子, 加藤芳朗, 田崎美弥子, 石井八重子, 海老原良典, 高山美智代, 広瀬信義, 折笠秀樹, 角

間辰之, 国吉緑, LeeJung Won, 鈴木千智, 藤井美和, 畑田けい子, 松田正巳, WHOQOL-OLD 調査票日本語

版開発グループ (2007)

WHOQOL-OLD調査票開発研究における重要性の調査票にみられた心疾患既往のある高齢者の特徴.

14

心臓リハビリテーション. 12(1): 154-157.

101. Chen X, Origasa H, Ichida F, Kamibeppu K, Varni JW (2007)

Reliability and validity of the Pediatric Quality of Life InventoryTM (PedsQLTM) short form 15

generic core scales in Japan.

Quality of Life Research, Online (July 7), DOI: 10.1007/s11136-007-9230-4.

Quality of Life Research. 16: 1239-1249.

102. 朱燕波、王琦、折笠秀樹 (2007)

中医体質量表的信度和効度評価

中国行動医学科学(Chin J Behavioral Med Sci). 16(7): 651-654.

103. Konno A, Nishio M, Origasa H (2007)

Oral pilocarpine for radiation-induced xerostomia: a randomized, double-blind,

placebo-controlled trial.

Jpn Pharmacol Ther. 35(suppl): S131-S140.

104. 菅井進、小池隆夫、宮坂信之、今野昭義、藤林孝司、住田孝之、川合眞一、折笠秀樹(2007)

シェーグレン症候群の口腔乾燥症に対するピロカルピン塩酸塩経口剤の第 II相用量反応試験.

Jpn Pharmacol Ther. 35(Suppl): S141-S153.

105. 菅井進、小池隆夫、宮坂信之、住田孝之、川合眞一、折笠秀樹(2007)

シェーグレン症候群の口腔乾燥症に対するピロカルピン塩酸塩経口剤の長期投与試験.

Jpn Pharmacol Ther. 35(Suppl): S155-S167.

106. Fukuda O, Hirashima Y, Origasa H, Endo S (2007)

Characteristics of helmet or knit cap use in head injury o snowboarders – analysis of 1,190

consective patients.

Neurologia medico-chirurgica. 47(11): 491-494.

107. 高橋千晶、奥寺敬、若杉雅浩、旭雄士、丹下大祐、岡澤成祐、坂本哲也、有賀徹、太田富雄、折笠秀樹(2007)

優れた Coma Scaleとは？ JCS, ECSの比較研究‐第一報.

Neurosurg Emerg. 12: 129-135.

108. Kurimoto M, Nagai S, Kamiyama H, Tsuboi Y, Kurosaki K, Hayashi N, Origasa H, Endo S (2007)

Prognostic factors in elderly patients with supratentorial malignant gliomas.


109.平島豊、栗本昌紀、堀恵美子、折笠秀樹、遠藤俊郎 (2007)

椎骨脳底動脈系破裂脳動脈瘤のくも膜下出血はテント上のものに比べて脳血管攣縮の頻度は少ないか?

脳血管攣縮, 22: 90-92, 2007Mar.

Year 2008

110. Uemura K, Hirashima Y, Kurimoto M, Kuwayama N, Kubo M, Origasa H, Doshi M, Endo S (2008)

Involvement of meteorological factors and sex in the occurrence of subarachnoid hemorrhage in

15

Japan.


111. Wang Q, Zhu Y, Origasa H, Du J, Pang G, Song X, Qian H, Xue H, Zhao J (2008)

Study on related influencing factors of phlegm-wetness constitution in Chinese medicine.

Journal of Beijing University of Traditional Chinese Medicine. 31(1): 10-13.

112. Shan L, Makita N, Xing Y, Watanabe S, Futatani T, Ye F, Saito K, Ibuki K, Watanabe K, Hirono K,

Uese K, Ichida F, Miyawaki T, Origasa H, Bowles NE, Towbin JA (2008)

SCN5A variants in Japanese patients with left ventricular noncompaction and arrhythmia.

Molecular Genetics and Metabolism. 93: 468-474.

113. Origasa H, Goto S, Uchiyama S, Shimada K, Ikeda Y, on behalf of the J-TRACE Investigators.

The Japan Thrombosis Registry for Atrial fibrillation, Coronary or Cerebrovascular Events

(J-TRACE): A nation-wide, prospective large cohort study; The study design.

Circulation Journal. 72(6): 991-997.

114. Hori E, Hayashi N, Hamada H, Masuoka T, Kuwayama N, Hirashima Y, Origasa H, Ohtani O, Endo S (2008)

A development of atheromatous plaque is restricted by characteristic arterial wall structure

at the carotid bifurcation.

Surgical Neurology. 69: 586-591.

115. Tanaka K, Ishikawa Y, Yokoyama M, Origasa H, Matsuzaki M, Saito Y, Matsuzawa Y, Sasaki J, Oikawa

S, Hishida H, Itakura H, Kita T, Kitabatake A, Nakaya N, Sakata T, Shimada K, Shirato K, for the

JELIS Investigators (2008)

Reduction in the recurrence of stroke by eicosapentaenoic acid (EPA) for hypercholesterolemic

patients: subanalysis of the JELIS trial.

Stroke. 39(7): 2052-2058.

116. Saito Y, Yokoyama M, Origasa H, Matsuzaki M, Matsuzawa Y, Ishikawa Y, Oikawa S, Sasaki J, Hishida

H, Itakura H, Kita T, Kitabatake A, Nakaya N, Sakata T, Shimada K, Shirato K, for the JELIS

Investigators (2008)

Effects of EPA on coronary artery disease in hypercholesterolemic patients with multiple

risk-factors: Sub-analysis of primary prevention cases from JELIS.


117. Zhu Y, Origasa H, Uebaba K, Xu F, Wang Q (2008)

Development and validation of the Japanese version of the Constitution in Chinese Medicine

Questionnaire (CCMQ).

Kampo Med. 59(6): 783-792.

118. 中村重信、佐々木健、阿瀬川孝治、伊丹昭、伊藤達彦、清原龍夫、河野和彦、松田桜子、水野裕、宮原覚、

折笠秀樹、遠藤英俊 (2008)

Ferulic acidと garden angelica 根抽出物製剤 ANM176TMがアルツハイマー病患者の認知機能に及ぼす影

16

響.

Geriatric Medicine. 46(12): 1511-1519.

Year 2009

119. Hatta M, Joho S, Inoue H, Origasa H (2009)

Health-related quality of life questionnaire in symptomatic patients with heart failure: validity

and reliability of a Japanese version of the MRF28.

Journal of Cardiology. 53: 117-126.

120. Watanabe K, Matsui M, Matsuzawa J, Tanaka C, Noguchi K, Yoshimura N, Hongo K, Ishiguro M, Watanabe

S, Hirono K, Uese K, Ichida F, Origasa H, Nakazawa J, Oshima Y, Miyawaki T, Matsuzaki T, Yagihara

T, Bilker W, Gur RC (2009)

Impaired neuroanatomic development in infants with congenital heart disease.

Journal of Thoracic Cardiovascular Surgery. 137: 146-153.

121. Shinohara Y, Nagayama M, Origasa H(2009)

External review of the Japanese guidelines for the management of stroke 2004.

Stroke. 40: 1439-1443.

122. Hirono K, Konishi T, Origasa H, Ichida F, Miyawaki T (2009)

Echocardiographic and electrocardiographic analyses of patients with severe motor and

intellectual disabilities.

Heart and Vessels. 24: 46-53.

123. Yamashita T, Ogawa S, Sato T, Aizawa Y, Atarashi H, Fujiki A, Inoue H, Ito M, Katoh T, Kobayashi

Y, Koretsune Y, Kumagai K, Niwano S, Okazaki O, Okamura K, Saku K, Tanabe T, Origasa H, for the

J-BAF Investigators (2009)

Dose-response effects of bepridil in patients with persistent atrial fibrillation monitored with

transtelephonic electrocardiograms: a multicenter, randomized, placebo-controlled,

double-blind study (J-BAF Study).

Circulation Journal. 73:1020-1027.

124. Matsuzaki M, Yokoyama M, Saito Y, Origasa H, Ishikawa Y, Oikawa S, Sasaki J, Hishida H, Itakura

H, Kita T, Kitabatake A, Nakaya N, Sakata T, Shimada K, Shirato K, Matsuzawa Y, for the JELIS


Incremental effect of eicosapentaenoic acid on cardiovascular events in statin-treated patients

with coronary artery disease: secondary prevention analysis from JELIS.


125. Ogawa H, Xu FH, Uebaba K, Origasa H, Kondoh K, Mikage M. (2009)

Antioxidative potentiality of a Kampo formulation measured by an ex vivo study.

Journal of Alternative and Complementary Medicine. 15(3): 267-74.

17

126. Hirono K, Kemmotsu Y, Wittkowski H, Foell D, Saito K, Ibuki K, Watanabe K, Watanabe S, Uese K, Kanegane

H, Origasa H, Ichida F, Roth J, Miyawaki T, Saji T (2009)

Infliximab reduce the cytokine-mediated inflammation but does not suppress cellular infiltration

of the vessel wall in refractory Kawasaki disease.

Pediatric Research. 65(6): 696-701.

127. Kasanuki H, Hagiwara N, Hosoda S, Sumiyoshi T, Honda T, Haze K, Nagashima M, Yamaguchi J, Origasa

H, Urashima M, Ogawa H, for the HIJ-CREATE Investigators (2009)

Angiotensin II receptor blocker-based vs. non-angiotensin II receptor blocker-based therapy in

patients with angiographically documented coronary artery disease and hypertension: the Heart

Institute of Japan Candesartan Randomized Trial for Evaluation in Coronary Artery Disease

(HIJ-CREATE).

European Heart Journal. 30(10):1203-12.

128. Kaku K, Tanaka S, Origasa H, Kikuchi M, Akanuma Y (2009)

Addition of mitiglinide to pioglitazone monotherapy improves overall glycemic control in Japanese

patients with type 2 diabetes: a randomized double blind trial.

Endocrine Journal. 56(5): 657-664.

129. Kaku K, Tanaka S, Origasa H, Kikuchi M, Akanuma Y (2009)

Effect of mitiglinide on glycemic control over 52 weeks in Japanese type 2 diabetic patients

insufficiently controlled with pioglitazone monotherapy.

Endocrine Journal. 56(6): 739-746.

130. Uchiyama S, Goto S, Matsumoto M, Nagai R, Origasa H, Yamazaki T, Shigematsu H, Shimada K, Yamada

N, Bhatt DL, Steg PG, Ikeda Y, on behalf of the REACH Registry Investigators (2009)

Cardiovascular event rates in patients with cerebrovascular disease and atherothrombosis at other

vascular locations : Results from 1-year outcomes in the Japanese REACH Registry.

Journal of the Neurological Sciences. 287(1-2) : 45-51.

131. Oikawa S, Yokoyama M, Origasa H, Matsuzaki M, Matsuzawa Y, Saito Y, Ishikawa Y, Sasaki J, Hishida

H, Itakura H, Kita T, Kitabatake A, Nakaya N, Sakata T, Shimada K, Shirato K, for the JELIS


Suppressive effect of EPA on the incidence of coronary events in hypercholesterolemia with

impaired glucose metabolism: sub-analysis of JELIS.


132. 古谷陽一、折笠秀樹、山本樹、中田真司、岡洋志、渡辺哲郎、引綱宏彰、嶋田豊 (2009)

インフルエンザ流行期における上気道感染の発症を予測できるか？ ―気虚に基づく診断モデルの提

案

漢方の臨床. 56(1): 99-106.

18

Year 2010

133. Origasa H, Yokoyama M, Matsuzaki M, Saito Y, Matsuzawa Y, on behalf of the JELIS Investigators (2010)

Clinical importance of adherence to treatment with eicosapentaenoic acid in patients with

hypercholesterolemia.


134. Teramoto T, Shimada K, Uchiyama S, Sugawara M, Goto Y, Yamada N, Oikawa S, Ando K, Ishizuka N, Yamazaki

T, Yokoyama K, Murata M, Ikeda Y (2010) (Origasa H, listed in the appendix as a member of data

monitoring committee of JPPP)

Rationale, design, and baseline data of the Japanese primary prevention project (JPPP) – a

randomized, open-label, controlled trial of aspirin versus no aspirin in patients with multiple

risk factors for vascular events.

Am Heart J. 159(3): 361-369.e4.

135. Inoue H, Nozawa T, Hirai T, Goto S, Origasa H, Shimada K, Uchiyama S, Hirabayashi T, Koretsune Y,

Ono S, Hasegawa T, Sasagawa Y, Ikeda Y, for the J-TRACE Investigators (2010)

Sex-related differences in the risk factor profile and medications of patients with atrial

fibrillation recruited in J-TRACE.


136. Uchiyama S, Shibata Y, Hirabayashi T, Mihara B, Hamashige N, Kitagawa K, Goto S, Origasa H, Shimada

K, Kobayashi H, Isozaki M, Ikeda Y, for the J-TRACE Investigators (2010)

Risk factor profiles in patients with stroke, myocardial infarction, and atrial fibrillation:

A Japanese multicenter cooperative registry.

Journal of Stroke and Cerebrovascular Diseases. 19(3): 190-197.

137. Ishikawa Y, Yokoyama M, Saito Y, Matsuzaki M, Origasa H, Oikawa S, Sasaki J, Hishida H, Itakura



The effects of eicosapentaenoic acid on coronary artery disease in patients with peripheral artery

disease: JELIS subgroup analysis.


138. Miyauchi K, Morino Y, Tsukahara K, Origasa H, Daida H, and PACIFIC steering committee members (2010)

The PACIFIC (Prevention of AtherothrombotiC incidents Following Ischemic Coronary attack)

Registry: Rational and design of a 2-year study in patients initially hospitalized with acute

coronary syndrome in Japan.

Cardiovascular Drugs and Therapy. 24(1): 77-83.

139. Higashi Y, Fujita M, Origasa H, Miyata T, Matsuo H, Naritomi H, Shigematsu H, on behalf of the SEASON


Study design of SEASON Registry: Prospective surveillance of cardiovascular events in

19

antiplatelet-treated arteriosclerosis obliterans patients in Japan (SEASON).

International Heart Journal, 51(5): 337-342, 2010.

140. Shiga T, Kasanuki H, Hagiwara N, Sumiyoshi T, Honda T, Haze K, Takagi A, Kawana M, Origasa H, Ogawa

H (2010)

Angiotensin receptor blocker-based therapy and cardiovascular events in hypertensive patients

with coronary artery disease and impaired renal function.

Blood Pressure, 19(6): 359-365.

Year 2011

141. Atarashi H, Inoue H, Okumura K, Yamashita T, Origasa H, for the J-RHYTHM Registry Investigators

(2011)

Investigation of optimal anticoagulation strategy for stroke prevention in Japanese patients

with atrial fibrillation – The J-RHYTHM Registry study design.

J Cardiol, 57: 95-99.

142. Takahashi C, Okudera H, Origasa H, Takeuchi E, Nakamura K, Fukuda O, Date I, Tokumori T, Aruga T,

Sakamoto T, Kobata H, Ohta T (2011)

A simple and useful coma scale for patients with neurologic emergencies: the Emergency Coma Scale.

American Journal of Emergency Medicine, 29(2): 196-202.

143.Itakura H, Yokoyama M, Matsuzaki M, Saito Y, Origasa H, Ishikawa Y, Oikawa S, Sasaki J, Hishida H,

Kita T, Kitabatake A, Nakaya N, Sakata T, Shimada K, Shirato K, Matsuzawa Y, for the JELIS


Relationship between plasma fatty acid composition and coronary artery disease.

Journal of Atherosclerosis and Thrombosis, 18(2): 99-107, 2011.

144.Shigehara K, Sugimoto K, Konaka H, Iijima M, Fukushima M, Maeda Y, Mizokami A, Koh E, Origasa H,

Iwammoto T, Namiki M (2011)

Androgen replacement therapy contributes to improving lower urinary tract symptoms in patients

with hypogonadism and benign prostate hypertrophy: a randomised controlled study.

Aging Male, 14(1): 53-58.

145.Atarashi H, Inoue H, Okumura K, Yamashita T, Kumagai N, Origasa H, for the J-RHYTHM Registry


Present status of anticoagulant treatment in Japanese patients with atrial fibrillation – A report

from the J-RHYTHM Registry.

Circulation Journal, 75: 1328-1333, 2011Jun.

146. Uchiyama S, Ikeda Y, Urano Y, Horie Y, Yamaguchi T.(Origasa H, listed in the appendix as a statistical

adviser) (2011)

The Japanese Aggrenox (extended-release dipyridamole plus aspirin) Stroke prevention versus

20

Aspirin Programme (JASAP) study: a randomized, double-blind, controlled trial.

Cerebrovascular Diseases, 31: 601-613.

147. Ogawa S, Shinohara Y, Kanmuri K. (Origasa H, listed in the appendix as a chair of data and safety

monitoring committee) (2011)

Safety and efficacy of the oral direct factor Xa inhibitor apixaban in Japanese patients with

non-valvular atrial fibrillation – The ARISTORLE-J Study-

Circulation Journal, 75: 1852-1859.

148. Origasa H, Goto S, Shimada K, Uchiyama S, Okada Y, Sugano K, Hiraishi H, Uemura N, Ikeda Y, on behalf

of the MAGIC Investigators (2011)

A prospective cohort study of gastrointestinal complications and vascular disease in patients

taking aspirin: rationale and design of the MAGIC study

Cardiovascular Diseases and Therapy, 25(6): 551-560, 2011Nov.

[Cardiovascular Diseases and Therapy (online) DOI 10.1007/s10557-011-6328-2, 13Aug2011.]

149.Kawahara M, Tada H, Tokoro A, Teramukai S, Origasa H, Kubota K, Shinkai T, Fukushima M, Furuse K

(2011)

Quality-of-life evaluation for advanced non-small-cell lung cancer: a comparison between

vinorelbine and gemcitabine followed by docetaxel versus paclitaxel and carboplatin regimens

in a phase III protocol: Japan Multinational Trial Organization LC00-03 (BRILC03-01).

BMC Cancer (online), 17 Aug 2011, 11: 356doi:10.1186/1471-2407-11-356.]

150. 小谷英太郎、奥村謙、井上博、山下武志、新博次、折笠秀樹 (2011)

我が国で用いられているプロトロンビン時間国際標準比(INR)測定用試薬の国際感度指数(ISI)値とそ

の問題点: J-RHYTHM Registryからの検討.

心電図, 31(3): 225-233.

151. J-RHYTHM Registry Investigators (Origasa H to be appeared in Appendix as a statistician) (2011)

Determinants of warfarin use and international normalized ratio levels in atrial fibrillation

patients in Japan: subanalysis of the J-RHYTHM Registry.


152. Goto S, Ikeda Y, Shimada K, Uchiyama S, Origasa H, Kobayashi H, on behalf of the J-TRACE Investigators

(2011)

One-year cardiovascular event rates in Japanese outpatients with myocardial Infarction, stroke,

and atrial fibrillation: results from the Japan Thrombosis Registry for Atrial Fibrillation,

Coronary, or Cerebrovascular Events (J-TRACE)

Circulation Journal, 75:2598-2604.

153. Inomata M, Kawagishi Y, Tokui K, Masaki Y, Taka C, Kambara K,Okazawa S, Imanishi S, Ichikawa T,

Suzuki K, Yamada T, Sumi S, Origasa H, Matsui S, Hayashi R, Tobe K.(2011)

A history of ischemic heart disease is common cause of wheezing in the elderly of a Japanese

21

local community.

Internal Medicine 50(24): 2975-2981.

Year 2012

154. Fukushima T, Urasaki Y, Yamaguchi M, Ueda M, Morinaga K, Haba T, Sugiyama T, Nakao S, Origasa H,

Umehara H, Ueda T.

A randomized comparison of modified intermediate-dose Ara-C versus High-dose Ara-C post remission

therapy for acute myeloid leukemia.

Anticancer Research 32(2): 643-647.

155. Sasaki J, Yokoyama M, Matsuzaki M, Saito Y, Origasa H, Ishikawa Y, Oikawa S, Itakura H, Hishida


Investigators.(2012)

Relationship between coronary artery disease and LDL-C and/or non HDL-C, and effect of highly

purified EPA on the risk of coronary artery disease in hypercholesterolemic patients under

treatment with statins: subanalysis of the Japan EPA Lipid Intervention Study (JELIS).

Journal of Atherosclerosis and Thrombosis, 19: 194-204.

156. Masuyama S, Tsujino T, Origasa H, Yamamoto K, Akasaka T, Hirano Y, Ohte N, Daimon T, Nakatani S,

Ito H.(2012)

Superiority of long-acting to short-acting loop diuretics in treatment of congestive heart

failure: the J-MELODIC study

Circulation Journal 76: 833-842.

(advanced publication: doi: 10.1253/circj.CJ-11-1500, March 16, 2012.)

157. Nakamura S, Sugiyama T, Matsumoto T, Iijima K, Ono S, Tajika M, Tari A, Kitadai Y, Matsumoto H,

Nagaya T, Kamoshida T, Watanabe N, Chiba T, Origasa H, Asaka M, for the Japan GAST Study Group.

Long-term outcome of gastric MALT lymphoma after eradication of Helicobacter pylori: a

multicenter cohort follow-up study of 420 patients in Japan.

Gut 61: 507-513, 2012Apr.

158. Suzuki N, Sato M, Houkin K, Terayama Y, Uchiyama S, Daida H, Shigematsu H, Goto S, Tanaka K, Origasa

H, Miyamoto S, Minematsu K, Matsumoto M, Okada Y.(2012)

One-year atherothrombotic vascular events rates in outpatients with recent non-cardioembolic

ischemic stroke: the EVEREST (Effective Vascular Event REduction after Stroke) Registry.

Journal of Stroke and Cerebrovascular Diseases 21: 245-253,.

(e-online, doi:10.1016/j.jstrokecerebrovasdis.2012.01.010.)

159. Ibuki K, Watanabe K, Yoshimura N, Kakimoto T, Matsui M, Yoshida T, Origasa H, Ichida F.(2012)

The improvement of hypoxia correlates with neuroanatomical and developmental outcomes:

comparison of midterm outcomes in infants with transposition of great arteries or

22

single-ventricle physiology.

Journal of Thoracic and Cardiovascular Surgery 143(5):1077-85.

160.許鳳浩、上馬場和夫、小川弘子、御影雅幸、折笠秀樹(2012)

漢方薬の代謝への作用の個人差：防風通聖散の二重盲検ランダム比較試験.

東方医学, 28(1): 37-59.

161. Itakura H, Yokoyama M, Matsuzaki M, Saito Y, Origasa H, Ishikawa Y, Oikawa S, Sasaki J, Hishida


Investigators. (2012)

The change in low-density lipoprotein cholesterol concentration is positively related to plasma

docosahexaenoic acid but not eicosapentaenoic acid.

Journal of Atherosclerosis and Thrombosis, 19(7): 673-679.

162. Yamashita T, Koretsune Y, Yasaka M, Inoue H, Kawai Y, Yamatuchi T, Uchiyama S, Matsumoto M, Ogawa

S (Origasa H, data and safety monitoring board member, appeared in Appendix)(2012)

Randomized, multicenter, warfarin-controlled phase II study of edoxaban in Japanese patients

with non-valvular atrial fibrillation.


163. Shinohara Y, Origasa H. (2012)

Post-stroke pneumonia prevention by angiotensin-converting enzyme inhibitors: Results of a

meta-analysis of five studies in Asians

Advances in Therapy 29(10):900-912.

164. Kamouchi M, Kumagai N, Okada Y, Origasa H, Yamaguchi T, Kitazono T, for the FSR Investigators. (2012)

A risk score for predicting recurrence in patients with ischemic stroke: The Fukuoka stroke risk

score for Japanese.

Cerebrovascular Diseases, 34: 351-357.

165. Zhu Y, Origasa H, Luo X, Wang Y, Di J, Lin L.(2012)

Responsiveness of three subjective report of outcome measures for chronic heart failure.

Journal of Chinese Integrative Medicine, 10(12): 1375-1381.

Year 2013

166. Yamamoto H, Origasa H, Hori M, on behalf of the J-DHF Investigators.(2013)

Effects of carvedilol on heart failure with preserved ejection fraction – The Japanese Diastolic

Heart Failure Study (J-DHF).

European Journal of Heart Failure, 15: 110-118. (e-pub, Sep 14, 2012)

167. Daida H, Miyauchi K, Ogawa H, Yokoi H, Matsumoto M, Kitakaze M, Kimura T, Matsubara T, Ikari Y,

Kimura K, Tsukahara K, Origasa H, Morino Y, Tsutsui H, Kobayashi M,Isshiki T.(2013)

Management and Two-year Long-term Clinical Outcomes of Patients with Acute Coronary Syndrome

23

in Japan: The Prevention of AtherothrombotiC Incidents Following Ischemic Coronary attack

(PACIFIC) Registry.

Circulation Journal, 77(4):934-943.

168. Sotozono C, Fukuda M, Ohishi M, Yano K, Origasa H, Kinoshita S, Shimomura Y. (2013)

Vancomycin ophthalmic ointment 1% for methicillin-resistant Staphylococcus aureus or

methicillin-resistant staphylococcus epidermidis infections: a case series.

BMJ Open, 2013; 3: e001206.

169. Sumi S, Origasa H, Houkin K, Terayama Y, Uchiyama S, Daida H, Shigematsu H, Goto S, Tanaka K, Miyamoto

S, Minematsu K, Matsumoto M, Okada Y, Sato M, Suzuki N.(2013)

A modified Essen stroke risk score for predicting recurrent cardiovascular events: development

and validation.

International Journal of Stroke, 8(4): 251-257.

170. Origasa H, Lee SH, Nakagawa H, Kumagai N, Fuse H, Tobe K.(2013)

Pioglitazone use and bladder cancer: hospital-based results from a nested case-control study

in Japan.

Jpn Pharmacol Ther, 41(7):663-667.

171. Kumagai N, Origasa H, Nagao T, Takekawa H, Okuhara Y, Yamaguchi T. (2013)

Prognostic significance of smoking in patients with acute ischemic stroke within 3 months of

onset.

Journal of Stroke and Cerebrovascular Diseases 22(6): 792-798.

172. Inoue H, Okamura K, Atarashi H, Yamashita T, Origasa H, Kumagai N, Sakurai M, Kawamura Y, Kubota

I, Matsumoto K, Kaneko Y, Ogawa S, Aizawa Y, Chinushi M, Kodama I, Watanabe E, Koretsune Y, Okuyama

Y, Shimizu A, Igasa O, Bando S, Fukatani M, Saikawa T, Chishaki A.(2013)

Target international normalized ratio values for preventing thromboembolic and hemorrhagic

events in Japanese patients with non-valvular atrial fibrillation: results of the J-RHYTHM

Registry

Circulation Journal, 77(9):2264-2270.

173. Taenaka N, Kikkawa S [Origasa H, listed as one of the trial members in Appendix](2013)

Dose-dependent effect of landiolol, a new ultra-short-acting β1-blocker, on supraventricular

tachyarrhythmias in postoperative patients.

Clinical Drug Investigation, 33: 505-514.

174. Kumagai N, Okuhara Y, Iiyama T, Fujimoto Y, Takekawa H, Origasa H, Kawanishi Y, Yamaguchi T.(2013)

Effects of smoking on outcomes after acute atherothrombotic stroke in Japanese men.

Journal of the Neurological Sciences, 335: 164-168.

175. Kumagai N, Hatta M, Okuhara Y, Origasa H.(2013)

Validation of general linear modeling for identifying factors associated with quality of life:

24

a comparison with structural equation modeling.

Health, 5(11): 1884-1888.

176. Saiki I, Koizumi K, Goto H, Inujima A, Namiki T, Raimura M, Kogure T, Tatsumi T, Inoue H, Sakai

S, Oka H, Fujimoto M, Shinohara K, Takeno N, Yamada M, Hoshina A, Oe M, Hikiami H, Sakurai H,

Shibahara N, Shimada Y, Origasa H. (2013)

The long-term effects of a Kampo medicine, Juzentaihoto, on maintenance of antibody titer in

elderly people after influenza vaccination.

Evidence-Based Complementary and Alternative Medicine (e-CAM), 2013:568074.

Year 2014

177. Nagai Y, Kohriyama T, Origasa H, Minematsu K, Yokota C, Uchiyama S, Ibayashi S, Terayama Y, Takagi

M, Kitagawa K, Nomura E, Hosomi N, Ohtsuki T, Yamawaki T, Matsubara Y, Nakamura M, Yamasaki Y,

Mori E, Fukushima M, Kobayashi S, Shinohara Y, Yamaguchi T, Matsumoto M, and J-STARS


Rationale, design and baseline features of a randomized controlled trial to assess the effects

of statin for the secondary prevention of stroke: The Japan statin treatment against recurrent

stroke (J-STARS).

International Journal of Stroke, 9: 232-239.

178. Nakamura M, Miyata T, Ozeki Y, Takayama M, Komori K, Yamada N, Origasa H, Satokawa H, Maeda H, Tanabe

N, Unno N, Shibuya T, Tanemoto K, Kondo K, Kojima T.(2014)

Current venous thromboembolism management and its outcomes in Japan: the nationwide JAVA

observational study.

Circulation Journal, 78(3): 708-717.

179. Inoue H, Atarashi H, Okumura K, Yamashita T, Origasa H, Kumagai N, Sakurai M, Kawamura Y, Kubota


Y, Shimizu A, Igawa O, Bando S, Fukatani M, Saikawa T, Chishaki A, on behalf of the J-RHYTHM Registry


Impact of gender on the prognosis of patients with nonvalvular atrial fibrillation.

American Journal of Cardiology, 113; 957-962.

180. Akizawa T, Origasa H, Kameoka C, Kaneko Y, Kawasaki S, and the Bixalomer Study Group.(2014)

Randomized controlled trial of bixalomer versus sevelamer hydrochloride in hemodialysis patients

with hyperphosphatemia.

Therapeutic Apheresis and Dialysis, 18(2): 122-131.

181. Uemura N, Sugano K, Hiraishi H, Shimada K, Goto S, Uchiyama S, Okada Y, Origasa H, Ikeda Y, and

the MAGIC Study Group.(2014)

Risk factor profiles, drug usage, and prevalence of aspirin-associated gastroduodenal injuries

25

among high-risk cardiovascular Japanese patients: the results from MAGIC study.

Journal of Gastroenterology, 49(5): 814-824.

182. Okumura K, Inoue H, Atarashi H, Yamashita T, Tomita H, Origasa H, for the J-RHYTHM Registry


Validation of CHA2DS2-VASc and HAS-BLED scores in Japanese patients with nonvalvular atrial

fibrillation: an analysis of the J-RHYTHM registry.


183. Zhu Y, Wang Q, Dai Z, Origasa H, Di J, Wang Y, Lin L, Fan C.(2014)

Case-control study on the associations between lifestyle-behavioral risk factors and

phlegm-wetness constitution.

Journal of Traditional Chinese Medicine. 34(3): 286-292.

184. Yamamoto K, Origasa H, Suzuki Y, Takahashi T, Shinozaki T, Watanabe T, Sakata Y, Izumi C, Taira

K, Hori M, on behalf of the J-DHF Investigators.(2014)

Left atrial dilatation predicts both of clinical outcomes and beneficial response to carvedilol

in heart failure with preserved ejection fraction: a report from the Japanese Diastolic Heart

Failure Study (J-DHF).

Journal of Cardiology, 63: 424-431.

185. Akizawa T, Origasa H, Kameoka C, Kaneko Y, Kawasaki S, and the Bixalomer Study Group.(2014)

Dose-finding study of bixalomer in patients with chronic kidney disease on hemodialysis with

hyperphosphatemia: a double-blind, randomized, placebo-controlled and sevelamer

hydrochloride-controlled open-label, parallel group study.

Therapeutic Apheresis and Dialysis, 18(Supplement 2): 24-32.

186. Yamamoto K, Takeuchi T, Yamanaka H, Ishiguro N, Tanaka Y, Eguchi K, Watanabe A, Origasa H, Iwai

K, Sakamaki Y, Miyasaka N, Koike T.(2014)

Efficacy and safety of certolizumab pegol without methotrexate co-adiministration in Japanese

patients with active rheumatoid arthritis: the HIKARI study.

Modern Rheumatology, 24(4): 561-566.

187. Nakamoto H, Fujita T, Origasa H, Isono M, Kurumatani H, Okada K, Kanoh H, Kiriyama T, Yamada S.(2014)

Sustained release tablet of orally-active prostacyclin analogue, beraprost sodium, (TRK-100STP)

phase IIb/III trial in the treatment of chronic kidney disease with primary glomerular disease

or nephrosclerosis (CASSIOPEIR): Rationale and study design.

BMC Nephrology, 15:153.

188. Yamamoto K, Takeuchi T, Yamanaka H, Ishiguro N, Tanaka Y, Eguchi K, Watanabe A, Origasa H, Shoji

T, Sakamaki Y, Miyasaka N, Koike T.(2014)

Efficacy and safety of certolizumab pegol plus methotrexate in Japanese rheumatoid arthritis

patients with an inadequate response to methotrexate: The J-RAPID randomized, placebo-controlled

26

trial.


189. Tanaka Y, Yamamoto K, Takeuchi T, Yamanaka H, Ishiguro N, Eguchi K, Watanabe A, Origasa H, Shoji

T, Miyasaka N, Koike T.(2014)

Long-term efficacy and safety of certolizumab pegol in Japanese rheumatoid arthritis patients

who could not receive methotrexate: 52-week results from an open-label extension of HIKARI study.


190. Tanaka Y, Yamamoto K, Takeuchi T, Yamanaka H, Ishiguro N, Eguchi K, Watanabe A, Origasa H, Shoji

T, Miyasaka N, Koike T.(2014)

Long-term efficacy and safety of certolizumab pegol in Japanese rheumatoid arthritis patients

with an inadequate response to methotrexate: 52-week results from an open-label extension of

J-RAPID study.


191. Inoue H, Atarashi H, Okumura K, Yamashita T, Kumagai N, Origasa H.(2014)

Thromboembolic events in paroxysmal versus permanent non-valvular atrial fibrillation: a

sub-analysis of the J-RHYTHM Registry.


192. Ikeda Y, Shimada K, Teramoto T, Uchiyama S, Yamazaki T, Oikawa S, Sugawara M, Ando K, Murata M,

Yokoyama K, Ishizuka N. [Origasa H , as a member of data monitoring committee, appeared in the

supplemental content] (2014)

Low-dose aspirin for primary prevention of cardiovascular events in Japanese patients 60 years

or older with atherosclerotic risk factors: a randomized clinical trial. JAMA, 312(23):

2510-2510.

193. 津谷喜一郎、湯川慶子、長澤道行、新井一郎、五十嵐中、折笠秀樹、鶴岡浩樹、福山哲、元雄良治、山崎

喜比古 (2014)

代替医療による間接的な健康被害の実態.

薬理と治療, 42(12): 1005-1014.

Year 2015

194. Tekeuchi T, Yamamoto K, Yamanaka H, Ishiguro N, Tanaka Y, Eguchi K, Watanabe A, Origasa H, Shoji

T, Miyasaka N, Koike T. (2015)

Early response to certolizumab pegol predicts long-term outcomes in patients with active

rheumatoid arthritis: results from the Japanese studies.


195. Toyoda K, Uchiyama S, Hoshino H, Kimura K, Origasa H, Naritomi H, Minematsu K, Yamaguchi T. (2015)

Cilostazol Stroke Prevention Study for Antiplatelet Combination (CSPS.com): a randomized,

27

open-label, parallel-group trial.

International Journal of Stroke, 10: 253-258.

196. Yamashita T, Inoue H, Okumura K, Atarashi H, Origasa H, for the J-RHYTHM Registry Investigators.

(2015)

Warfarin anticoagulation intensity in Japanese nonvalvular atrial fibrillation patients: a

J-RHYTHM registry analysis.

Journal of Cardiology, 65: 175-177.

197. Konaka H, Sugimoto H, Origasa H, Iwamoto T, Takemura T, Takeda Y, Shigehara K, Iijima M, Koh E,

Namiki N, and the EARTH study group. (2015)

Effects of long-term androgen replacement therapy on the physical and mental statuses of aging

males with late-onset hypogonadism: a multicenter, randomized controlled trial in Japan (EARTH

Study).

Asian Journal of Andology, 17: 1-10.

198. Sano H, Satoh A, Murayama Y, Kato Y, Origasa H, Inamasu J, Nouri M, Cherian I, Saito N, WFNS

Cerebrovascular Disease & Treatment Committee. (2015)

Modified world federation of neurosurgical societies subarachnoid hemorrhage grading system.

World Neurosurgery, 83(5): 801-807.

199. 田嶼尚子、西村理明、泉和生、林野泰明、折笠秀樹、野田光彦、植木浩二郎 (2015)

糖尿病合併症の実態把握とその抑制に関する大規模観察研究―研究計画と 2型糖尿病のベースラインデ

ータ; JCDP study 1―.

糖尿病、58(5): 346-357.

200. 西村理明、泉和生、林野泰明、折笠秀樹、野田光彦、植木浩二郎、田嶼尚子 (2015)

糖尿病合併症の実態把握とその抑制に関する大規模観察研究―１型糖尿病の登録時臨床像; JCDP study

2―.

糖尿病、58(6): 426-436.

201. Kazui H, Miyajima M, Mori E, Ishikawa M, on behalf of the SINPHONI-2 Investigators [Origasa H ,

as a trial statistician appeared in the Appendix] (2015)

Lumboperitoneal shunt surgery for idiopathic normal pressure hydrocephalus (SINPHONI-2): an

open-label randomized trial.

Lancet Neurology, 14(6): 585-594.

202. Chishaki A, Kumagai N, Takahashi N, Saikawa T, Inoue H, Okumura K, Atarashi H, Yamashita T, Origasa

H, Sakurai M, Kawamura Y, Kubota I, Matsumoto K, Kaneko Y, Ogawa S, Aizawa Y, Chinushi M, Kodama

I,Watanabe E, Koretsune Y, Okuyama Y, Shimizu A, Igawa O, Bando S, Fukatani M, on behalf of the

J-RHYTHM Registry Investigators. (2015)

Non-valvular atrial fibrillation patients with low CHADS2 scores benefit from warfarin therapy

according to propensity-score matching subanalysis using the J-RHYTHM registry.

28

Thrombosis Research, 136: 267-273n.

203. Zhu Y, Wang Q, Pang G, Lin L, Origasa H, Wang Y, Di J, Shi M, Fan C, Shi H.(2015)

Association between body mass index and health-related quality of life：The "Obesity Paradox"

in 21,218 adults of the Chinese general population.

PLOS ONE, DOI:10.1371/journal.pone.0130613.

204. Tomita H, Okumura K, Inoue H, Atarashi H, Yamashita T, Origasa H, Tsushima E.(2015)

Validation of risk scoring system excluding female gender from CHADS2VASc in Japanese patients

with non-valvular atrial fibrillation: a subanalysis of the J-RHYTHM registry.


205. Yamamoto K, Goto H, Hirao K, Nakajima A, Origasa H, Tanaka K, Tomobe M, Totsuka K. (2015)

Long-term safety of tocilizumab: results from 3 years follow-up postmarketing surveillance of

5573 patients with rheumatoid arthritis in Japan.

Journal of Rheumatology, 42(8): 1368-1375.

206. Tajima N, Noda M, Origasa H, Noto H, Yabe D, Fujita Y, Goto A, Fujimoto K, Sakamoto M, Haneda M.

(2015)

Evidence-based practice guideline for the treatment for diabetes in Japan 2013.

Diabetology International, 6(3): 151-187.

207. Hosomi N, Nagai Y, Kohriyama T, Ohtsuki T, Aoki S, Nezu T, Maruyama H, Sunami N, Yokota C, Kitagawa

K, Terayama Y, Takagi M, Ibayashi S, Nakamura M, Origasa H, Fukushima M, Mori E, Minematsu K,

Uchiyama S, Shinohara Y, Yamaguchi T, Matsumoto M, for the J-STARS collaborators. (2015)

The Japan Statin Treatment against Recurrent Stroke (J-STARS): a multicenter, randomized,

open-label, parallel-group study.

EBioMedicine 2(9): 1071-1078.

208. Koyama A, Fujita T, Gejyo F, Origasa H, Isono M, Kurumatani H, Okada K, Kiriyama T, Yamada S. (2015)

Orally active prostacyclin analogue beraprost sodium in patients with chronic kidney disease:

A randomized, double-blind, placebo-controlled, phase II dose finding trial.

BMC Nephrology, 16: 165.

209. Kodani E, Atarashi H, Inoue H, Okumura K, Yamashita T, Origasa H, on behalf of the J-RHYTHM Registry


Use of warfarin in elderly patients with non-valvular atrial fibrillation: subanalysis of the

J-RHYTHM registry.


210. Tomita H, Okumura K, Inoue H, Atarashi H, Yamashita T, Origasa H, on behalf of the J-RHYTHM Registry


Assessment of risk factors for bleeding in Japanese patients with non-valvular atrial

fibrillation receiving warfarin treatment: a subanalysis of the J-RHYTHM Registry.

29

International Journal of Cardiology, 201: 308-310.

211. Higashi Y, Azuma N, Takeishi Y, Minamino T, Kihara Y, Node K, Sata M, Fukumoto Y, Origasa H, Matsuo

H, Naritomi H, Fujita M, Shimizu W. (2015)

Effect of low-intensity pulsed ultrasound device, SX-1001, on clinical symptoms in Buerger

disease with limb ischemia: a multicenter, double-blind, parallel randomized clinical trial.

International Heart Journal, 56: 632-638.

212. Tajima N, Nishimura R, Izumi K, Hayashino Y, Origasa H, Noda M, Ueki K, on behalf of the Diabetes

Registry Configuration Committee and the Japan Diabetes Society. (2015)

A large-scale, observational study to investigate the current state of diabetes complications

and their prevention in Japan: research outline and baseline data for type 2 diabetes -JDCP Study

1.


Year 2016

213. Atsumi A, Yamamoto K, Takeuchi T, Yamanaka H, Ishiguro N, Tanaka Y, Eguchi K, Watanabe A, Origasa

H, Yasuda S, Yamanishi Y, Kita Y, Matsubara T, Iwamoto M, Shoji T, Okada T, van der Heijde D, Miyasaka

N, Koike T. (2016)

The first double-blind, randomized, parallel-group certolizumab pegol study in

methotrexate-naïve early rheumatoid arthritis patients with poor prognostic factors, C-OPERA,

shows inhibition of radiographic progression.

Annals of the Rheumatic Diseases, 75: 75-83.

214. Higashi Y, Miyata T, Shigematsu H, Origasa H, Fujita M, Matsuo H, Naritomi H, Matsuda H, Nakajima

M. (2016)

Baseline characterization of Japanese peripheral arterial disease patients; analysis on

prospective Surveillance of cardiovascular Events in Antiplatelet-treated arterioSclerosis

Obliterans patients in JapaN (SEASON).


215. Nishimura R, Izumi K, Hayashino Y, Origasa H, Noda M, Ueki K, Tajima N, on behalf of the Diabetes

Registry Configuration Committee and the Japan Diabetes Society. (2016)

A large-scale observational study to investigate the current status of diabetic complications and

their prevention in Japan: research outline and baseline data for type 1 diabetes -JDCP Study 2.




Secondary prevention of stroke with warfarin in patients with nonvalvular atrial fibrillation:

subanalysis of the J-RHYTHM Registry.

30

Journal of Stroke and Cerebrovascular Diseases, 25(3): 585-599.



Beneficial effect of non-vitamin K antagonist oral anticoagulants in patients with non-valvular

atrial fibrillation: results of the J-RHYTHM registry 2.


218. Inoue H, Kodani E, Atarashi H, Okumura K, Yamashita T, Origasa H, on behalf of the J-RHYTHM Registry


Impact of body mass index on the prognosis of Japanese patients with non-valvular atrial

fibrillation.

American Journal of Cardiology, 118: 215-221.

219. Watanabe E, Yamamoto M, Kodama I, Inoue H, Atarashi H, Okumura K, Yamashita T, Lip GYH, Okuyama

Y, Chishaki A, Kiyono K, Origasa H, on behalf of the J-RHYTHM Registry Investigators. (2016)

Net clinical benefit of adding aspirin to warfarin in patients with atrial fibrillation: insights

from the J-RHYTHM Registry.


220. Isomura T, Suzuki S, Origasa H, Hosono A, Suzuki M, Sawada T, Terao S, Muto Y, Koga T. (2016)

Liver-related safety assessment of green tea extracts in humans: a systematic review of randomized

controlled trials.

European Journal of Clinical Nutrition, 70(11): 1221-1229.

221. Takeuchi T, Yamamoto K, Yamanaka H, Ishiguro N, Tanaka Y, Eguchi K, Watanabe A, Origasa H, Kobayashi

M, Shoji T, Miyasaka N, Koike T. (2016)

Post-hoc analysis showing better clinical response with the loading dose of certolizumab pegol

in Japanese patients with active rheumatoid arthritis.


222. Inoue H, Atarashi H, Kodani E, Okumura K, Yamashita T, Origasa H, Sakurai M, Kawamura Y, Kubota


Y, Shimizu A, Igawa O, Bando S, Fukutani Mk Saikawa T, Chishaki A. (2016)

Regional differences in frequencies of anticoagulation therapy and thromboembolism among

Japanese patients with non-valvular atrial fibrillation: an analysis of the J-RHYTHM registry.


223. Noguchi K, Sakakibara M, Asakawa N, Kamiya K, Yoshitani T, Oba K, Miyauchi K, Nishizaki Y, Ogawa

H, Yokoi H, Matsumoto M, Kitakaze M, Kimura T,Matsubara T, Ikara Y, Kimura K, Origasa H, Isshiki

T, Daida H, Tsutsui H, on behalf of the PACIFIC investigators. (2016)

Higher HbA1c after discharge is an independent predictor of adverse outcomes in patients with

acute coronary syndrome: findings from the PACIFIC registry.

31


224. Kodani E, Atarashi H, Inoue H, Okumura K, Yamashita T, Otsuka T, Tomita H, Origasa H, on behalf

of the J-RHYTHM Registry Investigators. (2016)

Impact of blood pressure control on thromboembolism and major hemorrhage in patients with

non-valvular atrial fibrillation: subanalysis of the J-RHYTHM registry.

Journal of American Heart Association (JAHA), doi: 10.116/JAHA.116.004075.

225. Yokota S, Itoh Y, Morio T, Origasa H, Sumitomo N, Tomobe M, Tanaka K, Minota S. (2016)

Tocilizumab in systematic juvenile idiopathic arthritis in a real-world clinical setting: results

from a 1-year of postmarketing surveillance follow-up of 417 patients in Japan.

Annals of the Rheumatic Diseases, 75(9): 1654-60.

226. Ikeda T, Atarashi H, Inoue H, Uchiyama S, Kitazono T, Yamashita T, Shimizu W, Kamouchi M, Kaikita

K, Fukuda K, Origasa H, Sakuma I, Saku K, Okumura Y, Nakamura Y, Morimoto H, Matsumoto N, Tsuchida

A, Ako J, Sugishita N, Shimizu S, Shimokawa H, on behalf of the EXPAND Investigators. (2016)

The EXPAND Study: Evaluation of effectiveness and safety of Xa inhibitor, rivaroxaban for the

prevention of stroke and systemic embolism in a nationwide cohort of Japanese patients diagnosed

as non-valvular atrial fibrillation-

Tohoku Journal of Experimental Medicine, 240: 259-268.

227. Akizawa T, Origasa H, Kameoka C, Tsukada J, Kuroiwa K, Yamaguchi H. (2016)

Bixalomer in hyperphosphatemic patients with chronic kidney disease not on dialysis: phase 3

randomized trial.

Therapeutic Apheresis and Dialysis, 20(6): 588-597.

Year 2017

228. Kamioka H, Tsutani K, Origasa H, Yoshizaki T, Kitayuguchi J, Shimada M, Tang W, Takano-Ohmuro H.

(2017)

Quality of systematic reviews of the Foods with Function Claims (FFC) registered at the Consumer

Affairs Agency (CAA) web site in Japan: prospective systematic review.

Nutrition Research, 40: 21-31.

229. Kitagawa K, Hosomi N, Nagai Y, Kagimura T, Ohtsuki T, Origasa H, Minematsu K, Uchiyama S, Nakamura

M, Matsumoto M. (2017)

Reduction in high-sensitivity C-reactive protein levels in patients with ischemic stroke by statin

treatment: Hs-CRP Sub-study in J-STARS.


230. Toyoda K, Minematsu K, Yasaka M, Nagai Y, Hosomi N, Origasa H, Kitagawa K, Uchiyama S, Koga M, Matsumoto

M, and J-STARS Investigators. (2017)

32

The Japan Statin Treatment Against Recurrent Stroke (J-STARS) echo study: rationale and trial

protocol.

Journal of Stroke and Cerebrovascular Diseases, 26(3): 595-599.

231. Hayashino Y, Izumi K, Okamura S, Nishimura R, Origasa H, Tajima N. (2017)

Longer duration of diabetes and types of diabetes therapy in Japanese patients with type 2

diabetes: A Japan Diabetes Complication and its Prevention prospective study 3 (JDCP study 3).

Journal of Diabetes Investigation, 8(2): 243-249.

232. Atsumi T, Yamamoto K, Takeuchi T, Yamanaka H, Ishiguro N, Tanaka Y, Eguchi K, Watabane A, Origasa

H, Yasuda S, Yamanashi Y, Kita Y, Matsubara T, Iwamoto M, Shoji T, Togo O, Okada T, ver der Heijde

D, Miyasaka N, Koike T. (2017)

Clinical benefit of 1-year certolizumab pegol (CZP) add-on therapy to methotrexate treatment in

early rheumatoic arthritis patients was observed following CZP discontinuation: 2-year results

of the C-OPERA study, a phase III randomized trial.

Annals of Rheumatic Diseases, 76(8): 1348-1356.

233. Kawazu S, Kanazawa Y, Iwamoto Y, Katayama S, Origasa H, Kuzuya T, for the JEDIS Research Group.(2017)

Effect of antihyperglycemic drug monotherapy to prevent the progression of mild hyperglycemia in

early diabetic patients: the Japan Early Diabetes Intervention Study (JEDIS).

Diabetes International, 8(4): 350-365.

234. Yoshida M, Origasa H, Narihito S.(2017)

Comparison of silodosin versus tadalafil in patients with lower urinary tract symptoms associated

with benign prostatic hyperplasia.

Low Urin Tract Symptoms, 9(3): 176-186.

235. Kawasaki S, Origasa H, Tetens V, Kobayashi M.(2017)

Comparison of TachoSil and TachoComb in patients undergoing liver resection: a randomized,

double-blind, non-inferiority trial.

Langenbecks Archives of Surgery, 402: 591-598.

236. Kumagai N, Nusser JA, Inoue H, Okumura K, Yamashita T, Kubo T, Kitaoka H, Origasa H, Atarashi H,

on behalf of the J-RHYTHM Registry Investigators. (2017)

Effect of addition of a statin to warfarin on thromboembolic events in Japanese patients with

nonvalvular atrial fibrillation and diabetes mellitus.

American Journal of Cardiology, 120(2): 230-235.

237. Higashi Y, Miyata T, Shigematsu H, Origasa H, Fujita M, Matsuo H, Naritomi H, Matsuda H, Nakajima

M, Awano H. (2017)

Two-year follow-up of vascular events in peripheral arterial disease treated with antiplatelet agents:

a prospective observational multicenter cohort study (SEASON).

Scientific Reports, 7:6095.

33

238. Wang C, Hata Y, Hirono K, Takasaki A, Ozawa S, Nakaoka H, Saito K, Miyao N, Okabe M, Ibuki K, Nishida

N, Origasa H, Yu X, Bowles NE, Ichida F. (2017)

A wide and specific spectrum of genetic variants and genotype-phenotype correlations revealed by

next-generation sequencing in patients with left ventricular noncompaction.

Journal of the American Heart Association, 6:e006210.

239. Ito M, Maruyama Y, Kitamura K, Kobayashi T, Takahashi H, Yamanaka N, Harubuchi Y, Origasa H, Yoshizaki

T. (2017)

Randomized controlled trial of juzen-taiho-to in children with recurrent acute otitis media.

Auris Nasus Larynx, 44(4): 390-397.

240.Mizuno Y, Hattori N, Kondo T, Nomoto M, Origasa H, Takahashi R, Yamamoto M, Yanagisawa N.(2017)

A randomized double-blind placebo-controlled phase III trial of selegiline monotherapy for early

Parkinson's disease.

Clinical Neuropharmacology, 40(5): 201-207.

Year 2018

247. Mizuno Y, Shimoda S, Origasa H. (2018)

Long-term treatment of Parkinson's disease with levodopa and other adjunctive drugs.

Journal of Neural Transmission, 125(1): 35-43.



Impact of creatinine clearance outcomes in patients with non-valvular atrial fibrillation; a


European Heart Journal – Quality of Care and Clinical Outcomes, 4:59-68

249. Koga M, Toyoda K, Minematsu K, Yasaka M, Nagai Y, Aoki S, Nezu T, Hosomi N, Kagimura T, Origasa

H, Kamiyama K, Suzuki R, Ohtsuki T, Maruyama H, Kitagawa K, Uchiyama S, Matsumoto M. (2018)

Long-term effect of pravastatin on carotid intima-media complex thickness: the Japan J-STARS echo

study.

Stroke, 49(1): 107-113.



Impact of creatinine clearance outcomes in patients with non-valvular atrial fibrillation; a


European Heart Journal – Quality of Care and Clinical Outcomes, 4:59-68.

251. Hosomi N, Nagai Y, Kitagawa K, Nakagawa Y, Aoki S, Nezu T, Kagimura T, Maruyama H, Origasa H, Minematsu

K, Uchiyama S, Matsumoto M, and J-STARS collaborators. (2018)

Pravastatin reduces the risk of atherothrombotic stroke when administered within six months of an

34

initial stroke event.


252. Hamazaki K, Takamori A, Tsuchida A, Kigawa M, Tanaka T, Ito M, Adachi Y, Saito S, Origasa H, Inadera

H, and Japan Environment and Children’s Study (JECS) Group. (2018)

Dietary intake of fish and n-3 polyunsaturated fatty acids and risks of perinatal depression: The

Japan Environment and Children’s Study (JECS).

Journal of Psychiatric Research, 98: 9-16.

253. Hayashi T, Hayakawa Y, Koh M, Tomita T, Nagai S, Kashiwazaki D, Sugimori M, Origasa H, Kuroda S.

(2018)

Impact of a novel biomarker, T-LAK cell originating protein kinase (TOPK) expression on outcome in

malignant glioma.

Neuropathology, 38(2): 144-153.

254. Wada S, Koga M, Toyoda K, Minematsu K, Yasaka M, Nagai Y, Nezu T, Hosomi N, Kagimura T, Origasa

H, Kamiyama K, Suzuki R, Ohtsuki T, Maruyama H, Kitagawa K, Uchiyama S, Matsumoto M, on behalf of

the J-STARS echo study collaborators. (2018)

Factors associated with intima-media complex thickness of the common carotid artery in Japanese

noncardioembolic stroke patients with hyperlipidemia: The J-STARS echo study.


255. Hosomi N, Kitagawa K, Nagai Y, Nakagawa Y, Aoki S, Nezu T, Kagimura T, Maruyama H, Origasa H, Minematsu

K, Uchiyama S, Matsumoto M, for the J-STARS collaborators. (2018)

Desirable low-density lipoprotein cholesterol levels for preventing stroke recurrence: a post-hoc

analysis of J-STARS.

Stroke, 49(4): 865-871.

256. Hosokawa A, Ando T, Ogawa K, Ueda A, Yoshita H, Mihara H, Fujinami H, Kajiura S, Yabushita K, Horikawa

N, Kobayashi Y, Yoshioka A, Origasa H, Sugiyama T. (2018)

Phase I/II study of S-1 plus cisplatin alternating with S-1 plus docetaxel in patients with advanced

gastric cancer.

American Journal of Clinical Oncology, 41(10): 977-981.

257. Shimokawa H, Yamashita T, Uchiyama S, Kitazono T, Shimizu W, Ikeda T, Kamouchi M, Kakita K, Fukuda

K, Origasa H, Sakuma I, Saku K, Okumura Y, Nakamura Y, Morimoto H, Matsumoto N, Tsuchida A, Ako

I, Sugishita N, Shimizu S, Atarashi H, Inoue H. (2018)

The EXPAND study: efficacy and safety of rivaroxaban in Japanese patients with non-valvular atrial

fibrillation.


258. Haneda M, Noda M, Origasa H, Noto H, Yabe D, Fujita Y, Goto A, Kondo T, Araki E. (2018)

Japanese Clinical Practice Guideline for Diabetes 2016.

35

Diabetology International 9: 657-697.

259. Okumura Y, Fukuda I, Nakamura M, Yamada N, Takayama M, Maeda H, Yamashita T, Ikeda T, Mo M, Yamazaki

T, Hirayama A, on behalf of the J’xactly Investigators. [Origasa H, appeared in the end of paper

as a member of DSMB] (2018)

Design and rationale for the Japanese registry of rivaroxaban effectiveness and safety for the

prevention of recurrence in patients with deep vein thrombosis and pulmonary embolism (J’xactly)

study.

BMJ Open 8: e020286.

260. Inoue H, Kodani E, Atarashi H, Okumura K, Yamashita T, Origasa H, and J-RHYTHM Registry Investigators.

(2018)

Renal dysfunction affects anticoagulation control with warfarin and outcomes in Japanese elderly

patients with non-valvular atrial fibrillation.


261. Inoue H, Kodani E, Atarashi H, Okumura K, Yamashita T, Okuyama Y, Origasa H, and J-RHYTHM Registry


Time in therapeutic range and disease outcomes in elderly Japanese patients with non-valvular atrial

fibrillation.


（論文：原著） - u-toyama.ac.jp articles since...1 （論文：原著） year 1979...

Documents